Program
terallethrin
Also written as “M108”, “FG-M108” and “M108 monoclonal antibody”.
Its studies are mostly in Pancreatic Neoplasms · Stomach Neoplasms, led by FutureGen Biopharmaceutical (Beijing).
Furthest: phase 3, since Dec 11, 20233 company-led studies, 3 open or runningNext primary completion: Jan 11, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| FutureGen Biopharmaceutical (Beijing) | 33 open or running | phase 3since Dec 11, 2023 | May 12, 2021 | Jan 11, 2027phase 3 · NCT06177041 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 12, 2021First study: phase 1 study in Advanced Unresectable Solid TumorsFirst studyNCT04894825 · 152 planned · China
- Dec 11, 2023Phase 3 study in Stomach NeoplasmsNCT06177041 · 486 planned · China
- Jan 26, 2026Phase 3 study in Pancreatic NeoplasmsNCT07383922 · 524 planned · China
Ahead
- Jan 11, 2027Primary completion: phase 3 study in Stomach NeoplasmsNCT06177041
- Jun 30, 2030Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07383922
TargetBeta
CLDN18 →read by rule
“A monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| arcotatug tavatecanrule | Innovent Biologics | phase 3 | 5 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07383922Pancreatic Neoplasms · China | 3 | Not yet recruiting | Jun 30, 2030 | 524 |
| NCT06177041Stomach Neoplasms · China | 3 | Recruiting | Jan 11, 2027 | 486 |
| NCT04894825Advanced Unresectable Solid Tumors · China | 1 | Recruiting | Jul 30, 2024 | 152 |
How it is read
Names in the registry
- “M108”, 2 entries
- “FG-M108”, 1 entry
- “M108 monoclonal antibody”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.